178 related articles for article (PubMed ID: 29995286)
1. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
Ikeda M; Takahashi H; Kondo S; Lahn MMF; Ogasawara K; Benhadji KA; Fujii H; Ueno H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1169-1177. PubMed ID: 28451833
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.
Okusaka T; Morimoto M; Eguchi Y; Nakamura S; Iino S; Kageyama R
Drugs R D; 2023 Jun; 23(2):99-107. PubMed ID: 37188895
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
[TBL] [Abstract][Full Text] [Related]
9. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
12. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Oettle H; Kozloff M; Cleverly A; Smith C; Estrem ST; Gueorguieva I; Lahn MMF; Blunt A; Benhadji KA; Tabernero J
Br J Cancer; 2018 Nov; 119(10):1208-1214. PubMed ID: 30318515
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
[TBL] [Abstract][Full Text] [Related]
16. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Palmer DH; Ma YT; Peck-Radosavljevic M; Ross P; Graham J; Fartoux L; Deptala A; Studeny M; Schnell D; Hocke J; Loembé AB; Meyer T
Br J Cancer; 2018 May; 118(9):1162-1168. PubMed ID: 29563636
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
